## UNITED STATES SECURITIES AND EXCHANGE COMMISSION April 29, 2013

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Biogen Idec Inc.

File No. 0-19311 - CF#29291

Biogen Idec Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K/A filed on February 12, 2013.

Based on representations by Biogen Idec Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:

Exhibit 2.1 through February 12, 2016

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Tom Kluck Legal Branch Chief